You are here

FDA Approves Testosterone Gel Product

CORONA, Calif., Jan. 30 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI) , a leading specialty pharmaceutical company, announced today that it has received final approval from the United States (U.S.) Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for testosterone gel 1% CIII. Testosterone gel 1% CIII is the generic equivalent to Solvay Pharmaceutical's AndroGel, which is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. For the 12-months ending November 2005, Androgel 1% CIII had total U.S. sales of approximately $330 million, according to IMS Health data.

Watson has been awarded 180 days of marketing exclusivity for being the first to file an ANDA containing a paragraph IV certification for the product. Watson's market exclusivity will begin upon the earlier of a commercial launch or a final court decision concerning pending litigation between Watson and Unimed Pharmaceuticals, a division of Solvay Pharmaceuticals.

Source: Watson Pharmaceuticals, Inc.

Recent Headlines

Attacks Cancerous Cells, Leaves Healthy Tissues Alone
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens
Primary Immunodeficiencies Affect 250,000 People in U.S.
More Than 25% of Patients Responded to Xpovio/Dexamethasone Combo
Moderates Pre-diabetes Progression, Reduces Cholesterol Levels
​NCI Study: Radioactive Iodine Associated With Solid Tumors
Old Chemo Drug at High Doses Goads Immune System to Fight Lymphoma
Findings May Explain Apparent Opioid-Seeking Behavior, Opioid Overuse